A. Hebert, D. Glaab, and R. Schreiber, “A Phase 1 Open -Label Multicenter Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Calcipotriene Foam, 0.005% Applied Under Maximal Use Conditions in Adolescent Subjects with Plaque Psoriasis”, J of Skin, vol. 3, no. 2, p. 171, Mar. 2019.